Jason practices in the firm’s litigation section, and has experience in complex commercial litigation, including representing financial institutions, closely-held corporations and publicly traded companies. Additionally, Jason has experience drafting discovery responses and conducting and managing confidential document review for production. Jason has also worked on matters relating to investor disputes, government investigations, and enforcement proceedings.
During law school, Jason served as editor-in-chief of the Northeastern University Law Review. Also, Jason was a Summer Associate twice at Mintz in 2017 and 2018. He was a legal intern in the Global Litigation department of a Boston-based biopharmaceutical company.
Jason remains active in politics by continuing to serve as an advisor for various national, local, and state-wide candidates and elected officials. Prior to attending law school, Jason served as special assistant to U.S. Senator Elizabeth Warren (D-MA) and worked on Warren’s Senatorial campaigns.
Education
- Northeastern University (JD)
- University of Massachusetts - Amherst (BA, Legal Studies)
Recognition & Awards
- Richard G. and Clare E. Lesser Scholarship, Northeastern University School of Law (2019)
Involvement
- Board of Directors, Warren for President, Inc. (2018 – present)
- Board of Directors, South End Baseball (2018 – present)
- Board of Directors, UMass Amherst Alumni Association (2015 – 2018)
Recent Insights
Viewpoints
FINRA Will Look at “Good Faith Efforts” of Firms on Reg. BI Enforcement
July 9, 2020 |Blog
News & Press
Mintz Member Eóin Beirne and Associates Jason Burrell and Nicole Henry co-authored this Law360 expert analysis article examining trends and developments in criminal health care enforcement in 2019, such as opioid-related enforcement, kickbacks and medical necessity, medical devices, U.S. Department of Justice guidance, and more. The article also posits criminal health care enforcement trends for 2020, including the increased use of data-driven investigative tools, continued opioid prosecutions, and scrutiny of new technologies or novel ways of delivering medical care.
Viewpoints
FINRA Will Look at “Good Faith Efforts” of Firms on Reg. BI Enforcement
July 9, 2020 | Blog | By David L. Ward, Jason Burrell
The CFTC and NFA Issue No-Action Relief to FCMs and Introducing Brokers in Calculating Net Capital After Receiving of Covered PPP Loans under the CARES Act
April 24, 2020 | Blog | By Therese Doherty, Jason Burrell
On April 23, 2020, the CFTC announced a targeted no-action relief to certain market participants from compliance with net capital treatment of covered loans received under the Paycheck Protection Program (PPP) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (CARES Act).
Read more
The CFTC and NFA Offer Further No-Action Relief to Market Participants in Response to the Unprecedented Conditions Posed by COVID-19
April 3, 2020 | Blog | By Therese Doherty, Jason Burrell
On March 31, 2020, the CFTC extended temporary no-action relief to foreign affiliates of certain futures commission merchants (FCMs) in further response to the COVID-19 pandemic.
Read more
The CFTC Issued a Third Wave of No-Action Relief in View of the COVID-19 Pandemic and the NFA Followed Suit
March 24, 2020 | Alert | By Therese Doherty, Jason Burrell
This alert covers new DSIO temporary relief to a major insured depository institution (IDI) and commodity pool operators related to COVID-19 as well as temporary relief from the NFA to CPO members.
Read more
The CFTC and NFA Offer No-Action Relief to Market Participants Facing Unprecedented Conditions Posed by the COVID-19 Pandemic
March 19, 2020 | Advisory | By Therese Doherty, Jason Burrell
This alert outlines the conditions set forth in the DSIO and DMO’s no-action letters providing temporary relief to market participants facing COVID-19–related challenges.
Read more
Regulatory Update for NFA and FINRA Member Firms — COVID-19
March 18, 2020 | Alert | By Therese Doherty, Kara M. Cormier, Jason Burrell
This alert from the Mintz Financial Services Practice reviews the recent relief and guidance provided for NFA and FINRA member firms related to challenges posed by the COVID-19 pandemic.
Read more
Massachusetts Securities Division Rolls Out Final Version of Fiduciary Duty Rule
March 3, 2020 | Blog | By Pete Michaels, Michael Pastore, Jason Burrell, David L. Ward
The Massachusetts Securities Division (the “Division”) has announced that they will begin to apply a fiduciary conduct standard to broker-dealers and agents when dealing with their customers.
Read more
The New York City Bar Association Goes to Bat for Compliance Officers
February 13, 2020 | Blog | By Michael Pastore, Jason Burrell
The New York City Bar Association Compliance Committee (“Committee”) recently issued a report encouraging financial regulators to provide a clear framework for when compliance officers may be held personally liable for the misconduct of their employing institutions.
Read more
Health Care Enforcement Year-in-Review and 2020 Outlook: Criminal Case Developments
January 22, 2020 | Blog | By Eoin Beirne, Nicole Henry, Jason Burrell, Jane Haviland
As discussed in our article recently published by Law360, criminal health care enforcement in 2019 was in many ways a continuation of 2018, with opioid-related enforcement continuing to be the clear top priority for the Department of Justice (DOJ), in addition to DOJ's sustained focus on prosecuting individuals and data-driven identification of health care fraud. This post provides an overview of our article, which covers these issues and our expectations for 2020 in detail.
Read more
News & Press
2019 Trends In DOJ Health Care Enforcement
January 13, 2020
Mintz Member Eóin Beirne and Associates Jason Burrell and Nicole Henry co-authored this Law360 expert analysis article examining trends and developments in criminal health care enforcement in 2019, such as opioid-related enforcement, kickbacks and medical necessity, medical devices, U.S. Department of Justice guidance, and more. The article also posits criminal health care enforcement trends for 2020, including the increased use of data-driven investigative tools, continued opioid prosecutions, and scrutiny of new technologies or novel ways of delivering medical care.